Warning added to Gilead's Sovaldi, Harvoni after cardiac death
This article was originally published in Scrip
Executive Summary
Gilead Sciences warned prescribers on 20 March that co-administering the anti-arrhythmics agent amiodarone with the company's hepatitis C virus (HCV) treatments Sovaldi (sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) in combination with another direct acting antiviral (DAA) could be deadly.